Cipla to collaborate with US-based MEDRx for muscle relaxant drug

Cipla USA Inc, the wholly-owned subsidiary of the Mumbai-based pharmaceutical company Cipla, has signed a worldwide licensing agreement (except for East Asia) with MEDRx Company Limited (MEDRx) to further develop and commercialise MRX-4TZT, a tizanidine patch for the management of Spasticity. Tizanidine is a type of central analgesic (acts on the central nerves in the brain and the spinal cord to relieve muscle tonicity). This drug is used to alleviate discomfort from shoulder stiffness, back problems, frozen shoulder, tension headaches and other problems.

Under the terms of the agreement, MEDRx is eligible to receive up to $ 30 million cumulatively through upfront and developmental, regulatory, and commercial milestones payments. MEDRx will also receive tiered royalties on the net sales of commercialised licensed products.